Literature DB >> 18942755

Engineered lentiviral vector targeting astrocytes in vivo.

Angélique Colin1, Mathilde Faideau, Noelle Dufour, Gwennaelle Auregan, Raymonde Hassig, Thibault Andrieu, Emmanuel Brouillet, Philippe Hantraye, Gilles Bonvento, Nicole Déglon.   

Abstract

Astrocytes are involved in key physiological brain processes, such as glutamatergic transmission and energy metabolism, often altered in neurodegenerative diseases. Targeted gene expression in astrocytes is needed to assess the contribution of these cells to physiological processes and for the development of new therapeutic strategies. However, most of the viral vectors currently used for gene transfer in the central nervous system (CNS) are highly neurotropic. We used mokola pseudotyping to shift the tropism of lentiviral vectors toward astrocytes and a detargeting strategy with miRNA to eliminate residual expression in neuronal cells. In primary cultures, we showed that incorporating target sequences for the neuron-specific miR124 effectively abolished transgene expression in neurons post-transcriptionally. Targeted expression of the LacZ reporter gene in astrocytes was achieved in the hippocampus, striatum, and cerebellum of the adult mouse in vivo. As a proof-of-principle, this new lentiviral vector was used to either overexpress or downregulate (RNA interference) the glial glutamate transporter GLAST into striatal astrocytes in vivo. These vectors provide new opportunities for cell type-specific gene transfer in the CNS. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18942755     DOI: 10.1002/glia.20795

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  60 in total

Review 1.  Targeting specific cells in the brain with nanomedicines for CNS therapies.

Authors:  Fan Zhang; Yi-An Lin; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  J Control Release       Date:  2015-12-11       Impact factor: 9.776

Review 2.  Viral vectors for gene delivery to the central nervous system.

Authors:  Thomas B Lentz; Steven J Gray; R Jude Samulski
Journal:  Neurobiol Dis       Date:  2011-10-07       Impact factor: 5.996

Review 3.  MicroRNAs in neuronal communication.

Authors:  Guilherme Shigueto Vilar Higa; Erica de Sousa; Lais Takata Walter; Erika Reime Kinjo; Rodrigo Ribeiro Resende; Alexandre Hiroaki Kihara
Journal:  Mol Neurobiol       Date:  2014-01-03       Impact factor: 5.590

Review 4.  The therapeutic potential of microRNAs: disease modulators and drug targets.

Authors:  Ailbhe M McDermott; Helen M Heneghan; Nicola Miller; Michael J Kerin
Journal:  Pharm Res       Date:  2011-08-05       Impact factor: 4.200

Review 5.  Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications.

Authors:  Brian D Brown; Luigi Naldini
Journal:  Nat Rev Genet       Date:  2009-08       Impact factor: 53.242

Review 6.  Recent developments in the understanding of astrocyte function in the cerebellum in vivo.

Authors:  Tycho M Hoogland; Bernd Kuhn
Journal:  Cerebellum       Date:  2010-09       Impact factor: 3.847

7.  Intravesical treatment of advanced urothelial bladder cancers with oncolytic HSV-1 co-regulated by differentially expressed microRNAs.

Authors:  K-X Zhang; Y Matsui; C Lee; O Osamu; L Skinner; J Wang; A So; P S Rennie; W W Jia
Journal:  Gene Ther       Date:  2016-02-23       Impact factor: 5.250

8.  Connexin 30 sets synaptic strength by controlling astroglial synapse invasion.

Authors:  Ulrike Pannasch; Dominik Freche; Glenn Dallérac; Grégory Ghézali; Carole Escartin; Pascal Ezan; Martine Cohen-Salmon; Karim Benchenane; Veronica Abudara; Amandine Dufour; Joachim H R Lübke; Nicole Déglon; Graham Knott; David Holcman; Nathalie Rouach
Journal:  Nat Neurosci       Date:  2014-03-02       Impact factor: 24.884

Review 9.  A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme.

Authors:  Thomas Wirth
Journal:  World J Exp Med       Date:  2011-12-20

10.  Characterization of the BAC Id3-enhanced green fluorescent protein transgenic mouse line for in vivo imaging of astrocytes.

Authors:  Cassandra Lamantia; Marie-Eve Tremblay; Ania Majewska
Journal:  Neurophotonics       Date:  2014-09-12       Impact factor: 3.593

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.